Search Medical Condition
Please enter condition
Please choose location from dropdown

Epping, Australia Clinical Trials

A listing of Epping, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (135) clinical trials

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

The purpose of this research is to determine whether giving severely injured adults a drug called tranexamic acid (TXA) as soon as possible after injury will improve their chances of survival and their level of recovery at six months. After severe injury, a person may have uncontrolled bleeding that places ...

Phase

8.54 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD). This Phase 2 study is designed to evaluate the safety of two doses of CT1812 administered once daily for 6 months ...

Phase

9.35 miles

Learn More »

Pembrolizumab + CVA21 in Advanced NSCLC

Primary Objective & Hypothesis (1) Objective: To evaluate the safety of intravenous CVA21 in combination with pembrolizumab in patients with advanced NSCLC. Hypothesis Pembrolizumab in combination with intravenous CVA21 will be well tolerated in patients with advanced NSCLC. Secondary Objective & Hypothesis (1) Objective: i. To evaluate the efficacy of ...

Phase

10.0 miles

Learn More »

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

This is a phase 2 clinical trial of nivolumab combined with ipilimumab in subjects with rare cancers. This study will allow an evaluation of the clinical benefit, as measured by progression free survival (PFS) and overall survival (OS), provided by nivolumab combined with ipilimumab. If the safety profile is acceptable ...

Phase

10.0 miles

Learn More »

A Trial of KB004 in Patients With Glioblastoma

This is a study of drug KB004 in patients with recurrent glioblastoma (GBM). Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM ...

Phase

10.0 miles

Learn More »